Ayahuasca for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Ayahuasca for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A plant brew combining a mind-altering compound with substances from a vine that let it work when swallowed. The most notable signal is possible rapid easing of hard-to-treat depression after a single supervised session, plus reported well-being gains. The evidence is early and uneven; the risks are real and partly serious, and lawful access is limited. (Full Review)

Protocol

Research-Clinical Dose
~0.36–1.0 mg/kg DMT
Single supervised oral dose standardized to DMT content in a calm, monitored environment, typically with medical staff present.
Best Time of Day
Evening or night
Traditionally and clinically conducted in the evening or at night; the experience lasts several hours.
Single vs. Split Dosing
Single primary dose
Sometimes with a smaller supplemental "top-up" dose given by the practitioner; a facilitator-managed decision, not self-titration.
Time to effect
Mood/Well-Being Benefits
Hours to days
Reported in studies to emerge within hours to days of a session; may persist for days to weeks, durability beyond uncertain.
Acute Effects Onset
30–60 minutes
Effects begin within 30–60 minutes of ingestion; peak around 1.5–2 hours.
Acute Effects Resolve
4–6 hours
The acute experience resolves within 4–6 hours, defining the supervised observation window.

Benefits

Contraindications
  • Personal or family history of psychotic disorders or bipolar disorder
  • Significant cardiovascular disease (recent myocardial infarction <90 days, uncontrolled hypertension, serious arrhythmia)
  • Pregnancy and breastfeeding
  • Significant liver disease (Child-Pugh Class B or C)
  • Serotonergic medication without a completed supervised washout
  • Sympathomimetic decongestants (pseudoephedrine, phenylephrine), dextromethorphan, stimulants (amphetamines, cocaine)
    •
Key Interactions
  • Antidepressants and serotonergic drugs (SSRIs, SNRIs, MAO inhibitors, tricyclics, St. John's Wort)
  • Tyramine-rich foods (aged cheeses, cured meats, fermented soy, some fermented beverages)
  • Serotonin precursors and serotonergic supplements (5-HTP, L-tryptophan, SAMe)
  • Supplements with additive effects (5-HTP, St. John's Wort, high-dose yohimbine)
  • Alcohol, other recreational drugs, other psychedelics
    •

Risk & Side Effects

  • High: Acute gastrointestinal effects (vomiting and diarrhea); acute cardiovascular stimulation; acute psychological distress ("bad trips")
    •
  • Medium: Serotonin toxicity from drug interactions; precipitation or worsening of psychiatric conditions
    •
  • Low: Risks from unregulated settings and adulteration
    •
  • Speculative: Long-term neurocognitive effects; hepatic effects from β-carbolines
    •

Monitoring

Marker Target Why
Blood Pressure <120/80 mmHg Acute use raises BP; screens cardiovascular risk
Resting Heart Rate 50–70 bpm Acute use raises heart rate; flags arrhythmia risk
ALT / AST (liver enzymes) ALT <25 U/L (men), <20 U/L (women) β-carbolines are hepatically processed; screens liver health
Comprehensive Metabolic Panel Within standard limits Assesses electrolytes/kidney status given vomiting and diarrhea risk
Medication/Serotonergic Review None active Confirms washout of SSRIs/SNRIs/MAOIs before use

Cadence: Session-anchored, not continuous: reassess blood pressure and heart rate immediately before and during a session, re-screen medications before every session, and repeat liver enzymes only if repeated use is planned (e.g., every 6–12 months for frequent users).

Qualitative Assessment

  • Mood and depressive symptoms: sustained improvement over days to weeks, ideally tracked with a validated mood scale
  • Anxiety and rumination: reduced repetitive negative thinking and improved emotional regulation
  • Well-being and life satisfaction: durable gains in subjective well-being and acceptance
  • Substance use: reduction in problematic alcohol, tobacco, or drug use where relevant
  • Tolerability: absence of persisting perceptual disturbance, distress, or sleep disruption
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.